Analysis of Bone Phenotype Differences in MEN1-Related and Sporadic Primary Hyperparathyroidism Using 3D-DXA

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Nov 9

PMID 39518523

Authors

Anna K Eremkina

Svetlana V Pylina

Alina R Elfimova

Anna M Gorbacheva

Ludovic Humbert

Mirella Lopez Picazo

Angelina V Hajrieva

Ekaterina N Solodovnikova

Liliya D Kovalevich

Ekaterina A Vetchinkina

Ekaterina V Bondarenko

Natalia V Tarbaeva

Natalia G Mokrysheva

Affiliations

Soon will be listed here.

Abstract

The rarity and variability of MEN1-related primary hyperparathyroidism (mPHPT) has led to contradictory data regarding the bone phenotype in this patient population. A single-center retrospective study was conducted among young age- and sex-matched patients with mPHPT and sporadic hyperparathyroidism (sPHPT). The main parameters of calcium-phosphorus metabolism, bone remodeling markers, and bone mineral density (BMD) measurements were obtained during the active phase of hyperparathyroidism before parathyroidectomy (PTE) and 1 year after. Trabecular Bone Score (TBS) and 3D-DXA analysis of the proximal femur were used to evaluate the differences in bone architecture disruption between groups. Patients with mPHPT had significant lower preoperative BMD compared to sPHPT at lumbar spine-LS ( = 0.002); femur neck-FN ( = 0.001); and total hip-TH ( = 0.002). 3D-DXA analysis showed the prevalence of cortical rather than trabecular bone damage in mPHPT compared to sPHPT: cortical thickness ( < 0.001); cortical surface BMD ( = 0.001); cortical volumetric BMD ( = 0.007); and trabecular volumetric BMD ( = 0.029). One year after, PTE DXA and 3D-DXA parameters were similar between groups, while 3D-visualisation showed more extensive regeneration in cortical sBMD and cortical thickness in mPHPT. mPHPT is associated with lower preoperative BMD values with predominant architecture disruption in the cortical bone. The absence of differences in DXA and 3D-DXA parameters 1 year after PTE between mPHPT/sPHPT combined with significantly lower BMD in mPHPT at the initial stage may indicate faster bone recovery after surgery in mPHPT than in sPHPT.

References

Pieterman C, van Hulsteijn L, den Heijer M, van der Luijt R, Bonenkamp J, Hermus A . Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. Ann Surg. 2012; 255(6):1171-8. DOI: 10.1097/SLA.0b013e31824c5145. View

Agarwal S, Kester M, Debelenko L, Heppner C, Emmert-Buck M, Skarulis M . Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet. 1997; 6(7):1169-75. DOI: 10.1093/hmg/6.7.1169. View

Thakker R, Newey P, Walls G, Bilezikian J, Dralle H, Ebeling P . Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9):2990-3011. DOI: 10.1210/jc.2012-1230. View

Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P . Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021; 17(4):207-224. DOI: 10.1038/s41574-021-00468-3. View

Cardinal J, Bergman L, Hayward N, Sweet A, Warner J, Marks L . A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. J Med Genet. 2005; 42(1):69-74. PMC: 1735899. DOI: 10.1136/jmg.2003.017319. View

Marini F, Giusti F, Cioppi F, Maraghelli D, Cavalli T, Tonelli F . Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy. Cells. 2021; 10(8). PMC: 8391385. DOI: 10.3390/cells10081895. View

Kong J, Wang O, Nie M, Shi J, Hu Y, Jiang Y . Clinical and Genetic Analysis of Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism in Chinese. PLoS One. 2016; 11(11):e0166634. PMC: 5112846. DOI: 10.1371/journal.pone.0166634. View

Lourenco Jr D, Toledo R, Mackowiak I, Coutinho F, Cavalcanti M, Correia-Deur J . Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur J Endocrinol. 2008; 159(3):259-74. DOI: 10.1530/EJE-08-0153. View

Kenkre J, Bassett J . The bone remodelling cycle. Ann Clin Biochem. 2018; 55(3):308-327. DOI: 10.1177/0004563218759371. View

10.

Vu T, Wang X, Wang Q, Cusano N, Irani D, Silva B . New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. Bone. 2013; 55(1):57-63. PMC: 4308951. DOI: 10.1016/j.bone.2013.03.009. View

11.

Poncin J, Abs R, Velkeniers B, Bonduelle M, Abramowicz M, Legros J . Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Hum Mutat. 1999; 13(1):54-60. DOI: 10.1002/(SICI)1098-1004(1999)13:1<54::AID-HUMU6>3.0.CO;2-K. View

12.

Lourenco Jr D, Coutinho F, Toledo R, Montenegro F, Correia-Deur J, Toledo S . Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010; 25(11):2382-91. DOI: 10.1002/jbmr.125. View

13.

Mamedova E, Mokrysheva N, Vasilyev E, Petrov V, Pigarova E, Kuznetsov S . Primary hyperparathyroidism in young patients in Russia: high frequency of hyperparathyroidism-jaw tumor syndrome. Endocr Connect. 2017; 6(8):557-565. PMC: 5633061. DOI: 10.1530/EC-17-0126. View

14.

Klementieva N, Goliusova D, Krupinova J, Yanvarev V, Panova A, Mokrysheva N . A Novel Isogenic Human Cell-Based System for MEN1 Syndrome Generated by CRISPR/Cas9 Genome Editing. Int J Mol Sci. 2021; 22(21). PMC: 8584395. DOI: 10.3390/ijms222112054. View

15.

Kihara M, Miyauchi A, Ito Y, Yoshida H, Miya A, Kobayashi K . MEN1 gene analysis in patients with primary hyperparathyroidism: 10-year experience of a single institution for thyroid and parathyroid care in Japan. Endocr J. 2009; 56(5):649-56. DOI: 10.1507/endocrj.k08e-265. View

16.

Gortz B, Roth J, Speel E, Krahenmann A, de Krijger R, Matias-Guiu X . MEN1 gene mutation analysis of sporadic adrenocortical lesions. Int J Cancer. 1999; 80(3):373-9. DOI: 10.1002/(sici)1097-0215(19990129)80:3<373::aid-ijc7>3.0.co;2-b. View

17.

Song A, Chen R, Guan W, Yu W, Yang Y, Wang J . Trabecular Bone Score as a More Sensitive Tool to Evaluate Bone Involvement in MEN1-related Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2023; 109(1):135-142. DOI: 10.1210/clinem/dgad460. View

18.

Altieri B, Di Dato C, Modica R, Bottiglieri F, Di Sarno A, Pittaway J . Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. Nutrients. 2020; 12(4). PMC: 7230756. DOI: 10.3390/nu12041021. View

19.

Canaff L, Vanbellinghen J, Kanazawa I, Kwak H, Garfield N, Vautour L . Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA. J Clin Endocrinol Metab. 2011; 97(2):E282-91. DOI: 10.1210/jc.2011-0241. View

20.

Lourenco Jr D, Coutinho F, Toledo R, Goncalves T, Montenegro F, Toledo S . Biochemical, bone and renal patterns in hyperparathyroidism associated with multiple endocrine neoplasia type 1. Clinics (Sao Paulo). 2012; 67 Suppl 1:99-108. PMC: 3329618. DOI: 10.6061/clinics/2012(sup01)17. View